CARGO to End Phase 2 Study of Firi-cel; Advances Remaining Programs, Evaluating Strategic Options

 

• CARGO elects to discontinue FIRCE-1, a Phase 2 clinical study of firicabtagene autoleucel (firi-cel)1; Company believes results do not support a competitive benefit-risk profile for patients.
• CARGO to implement a workforce reduction of approximately 50%.
• Phase 1 dose escalation study enrollment for CRG-023 on track to initiate in Q2 2025.

https://www.globenewswire.com/news-release/2025/01/29/3017565/0/en/CARGO-Therapeutics-to-Discontinue-FIRCE-1-Phase-2-Study-of-Firi-cel-Advances-Remaining-Programs-While-Evaluating-Strategic-Options.html